By focusing too heavily on family history, the Preventive Services Task Force is missing many opportunities for prevention, patient advocates, industry players, and researchers say.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
The researchers are developing a web-based tool to help physicians predict their patients' relapse risk and are planning clinical trials to study outcomes.
Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.
A statement from NIH Director Francis Collins follows a call by scientists for the moratorium pending the creation of a framework to guide the use of heritable genome editing.
The company shared details of its methods and results of some internal experiments but has been met with skepticism by members of the research community.
UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.
LUNGevity will promote the donation of excess lung cancer tissue and fluid samples to boost the Broad's efforts to develop next-generation research models.
The company — a spinout of the New York Genome Center — said it will use the funding in part to develop its technologies for new applications in agriculture.
Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers.
Breakthrough UV-C Performance Enables Better Control for Lab Managers
This white paper makes the case for why UV LED technology deserves serious consideration by RNA sequencing labs for controlling ribonuclease in a laboratory setting. It describes Phoseon’s findings related to LED light engines for the inactivation of RNases in a laboratory setting.
Clinical laboratories are increasingly adopting molecular assays as an alternative to the tedious, time-consuming stool cultures that have long been the mainstay for testing patients who might have infectious diarrhea or conditions such as Salmonella or Campylobacter. With an estimated 1.7 billion cases of childhood diarrheal disease occurring annually around the world, this is a significant advance for gastroenteritis testing.
